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Abstract
Importance—Identifying patients at risk of chronic kidney disease (CKD) progression may 
facilitate more optimal nephrology care. Kidney failure risk equations (KFREs) were previously 
developed and validated in two Canadian cohorts. Validation in other regions and in CKD 
populations not under the care of a nephrologist is needed.
Objective—To evaluate the accuracy of the KFREs across different geographic regions and 
patient populations through individual-participant data meta-analysis.
Data Sources—Thirty-one cohorts, including 721,357 participants with CKD Stages 3–5 in 
over 30 countries spanning 4 continents, were studied. These cohorts collected data from 1982 
through 2014.
Study Selection—Cohorts participating in the CKD Prognosis Consortium with data on end-
stage renal disease.
Data Extraction and Synthesis—Data were obtained and statistical analyses were performed 
between July 2012 and June 2015. Using the risk factors from the original KFREs, cohort-specific 
hazard ratios were estimated, and combined in meta-analysis to form new “pooled” KFREs. 
Original and pooled equation performance was compared, and the need for regional calibration 
factors was assessed.
Main Outcome and Measure—Kidney failure (treatment by dialysis or kidney 
transplantation).
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Results—During a median follow-up of 4 years, 23,829 cases of kidney failure were observed. 
The original KFREs achieved excellent discrimination (ability to differentiate those who 
developed kidney failure from those who did not) across all cohorts (overall C statistic, 0.90 (95% 
CI 0.89–0.92) at 2 years and 0.88 (95% CI 0.86–0.90) at 5 years); discrimination in subgroups by 
age, race, and diabetes status was similar. There was no improvement with the pooled equations. 
Calibration (the difference between observed and predicted risk) was adequate in North American 
cohorts, but the original KFREs overestimated risk in some non-North American cohorts. 
Addition of a calibration factor that lowered the baseline risk by 32.9% at 2 years and 16.5% at 5 
years improved the calibration in 12/15 and 10/13 non-North American cohorts at 2 and 5 years, 
respectively (p=0.04 and p=0.02).
Conclusions and Relevance—KFREs developed in a Canadian population showed high 
discrimination and adequate calibration when validated in 31 multinational cohorts. However, in 
some regions the addition of a calibration factor may be necessary.
Introduction
Chronic kidney disease (CKD) is increasing in incidence and prevalence worldwide.1 Rates 
of progression to kidney failure varies among individuals with CKD and depends on the 
severity of kidney disease, comorbid conditions, and risk of dying before kidney failure 
onset.2,3 Interventions to slow CKD progression, planning for initiation of dialysis and 
transplantation planning, and early creation of arteriovenous fistula have been advocated, 
but these strategies may be expensive and are associated with risks. Treatment would ideally 
be recommended only for patients at high risk of progression and where the benefit exceeds 
the harm.4,5
Tangri et al previously developed kidney failure risk equations (KFREs), which use 
demographic and laboratory data to predict progression of CKD to kidney failure.6 The 
KFREs were developed in 3,449 patients with CKD Stages 3–5 referred for nephrology care 
in Ontario, Canada, and validated in referred patients with CKD in British Columbia, 
Canada. The preferred KFREs (the 4-variable and 8-variable equations) are age-, sex- and 
laboratory value-based, thereby enabling automated risk reporting whenever laboratory tests 
are performed.7 The 4-variable equation requires age, sex, estimated glomerular filtration 
rate (eGFR), and urinary albumin-to-creatinine ratio (ACR), facilitating integration into 
clinical practice.
The KFREs are widely used through electronic applications (e.g., www.qxmd.com/kfre), 
with some initial validation in other countries and health care systems.7–12 However, 
widespread adoption of the KFREs requires validation in additional populations including 
non-white ethnicities, patients not under nephrology care, and cohorts outside North 
America. The accuracy of the KFREs in different geographic regions and patient 
populations is evaluated here.
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Methods
Participating Cohorts
Thirty-one cohorts participating in the Chronic Kidney Disease Prognosis Consortium 
(CKD-PC) were selected for KFRE validation based on data availability.13 The CKD-PC is 
a collaborative research group integrating data from more than 50 cohorts spanning 40 
countries and 2 million individuals.13 The diverse cohorts in the CKD-PC include 
populations across a wide range of baseline risk. For the purpose of this analysis, cohorts 
were selected to include patients with CKD Stages 3–5 [estimated glomerular filtration rate 
(eGFR) <60 ml/min/1.73 m2] and absence of kidney failure at baseline who had follow-up 
information on kidney failure, defined as treatment by dialysis or a kidney transplant. Data 
transfer and analysis took place between July 2012 and June 2015; included cohorts 
collected data from September 1982 through October 2014. This study was approved for use 
of de-identified data by the institutional review board at the Johns Hopkins Bloomberg 
School of Public Health, and the need for informed consent was waived.
Measurement of Variables in Cohorts
As in the original KFREs, GFR was estimated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) 2009 creatinine equation.14 Serum creatinine 
concentrations were standardized to isotope dilution mass spectrometry traceable methods 
where possible.14 For studies where creatinine measurements were not standardized to 
isotope dilution mass spectrometry, the creatinine levels were reduced by 5%, as previously 
reported.15,16 Albuminuria was represented as a log-transformed urine ACR. Alternative 
measures of urine protein excretion (protein-to-creatinine ratio, 24 hour urine collection, 
urinary dipstick) were transformed to the ACR using previously developed equations.6,17,18 
When available, baseline values for serum albumin, phosphorous, calcium, and bicarbonate, 
as well as physical examination measures of weight, systolic and diastolic blood pressure 
were derived from each cohort. Age, sex and ethnicity (black/non-black), as well as the 
presence of diabetes and hypertension, were also derived from the individual cohorts, with 
information on race collected as part of routine clinical care for the health systems and as 
demographic data for the study cohorts. Diabetes was defined as fasting glucose of at least 
7.0 mmol/L, non-fasting glucose of at least 11.1 mmol/L or glycated haemoglobin (HbA1c) 
of at least 6.5%, use of glucose-lowering drugs, or self-reported diabetes. Hypertension was 
defined as a systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at 
least 90 mm Hg, or use of antihypertensive drugs for treatment of hypertension. Potential 
participants missing any baseline data were excluded from analysis. Information on 
individual cohorts is provided in eAppendix 1.
Statistical Analysis
There were four KFREs developed in the original cohorts: the 3-variable (age, sex, and 
eGFR), the 4-variable (3-variable + ACR), the 6-variable (4-variable + diabetes and 
hypertension), and the 8-variable (4-variable + calcium, phosphate, bicarbonate, and 
albumin). The 4-variable and 8-variable KFREs demonstrated the best performance in the 
original cohorts; thus, the focus of this validation effort centered on the 4-variable and 8-
variable equations.
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Participant-level data were analyzed for each individual cohort, and then meta-analysis was 
performed across studies using a random-effects model. Risk-relationships observed in the 
original cohorts were compared to those seen in the validation cohorts. Cox proportional 
hazards models were fit using the variables included in each of the original KFREs within 
each study, allowing both the regression coefficients and the baseline hazard to vary. All 
variables were centered (age 70 years, 56% male, eGFR 36 ml/min/1.73 m2, ACR 170 mg/g, 
phosphate 3.9 mg/dL, albumin 4.0 g/dL, bicarbonate 25.6 mEq/L, and calcium 9.4 mg/dL), 
as per the original study.6 The “refit” coefficients were then pooled across studies using 
random-effects meta-analysis. Pooled and original coefficients were compared using the z-
test.19
Next, a set of “pooled” KFREs were developed to compare with the original KFREs. Pooled 
coefficients from the random-effects meta-analysis were combined with a pooled baseline 
hazard, defined as the average “refit” baseline hazard weighted by the number of kidney 
failure events.
Discrimination of the original and pooled KFREs was assessed using Harrell’s C statistic 
within each study, which was then meta-analyzed using random-effects models. 
Performance was also evaluated in predetermined subgroups of black/non-black race, 
presence or absence of diabetes mellitus, and age older/younger than 65 years. The 
discrimination of the original and pooled KFREs was compared by assessing the meta-
analyzed difference in C statistic within individual studies. Finally, within each set of 
original and pooled KFREs, the discrimination of the 4- versus 6- and 4- versus 8-variable 
KFREs was compared by meta-analyzing the difference in individual study C statistics (6-
variable performance is reported in the supplementary materials).
Calibration (the difference between observed and predicted risk) was examined by plotting 
the observed 2-year and 5-year probability of kidney failure in individual cohorts and 
comparing it to the predicted risk using the original and pooled KFREs. This was done in 5 
risk categories: for 2 years, 0 to <2%, 2 to <6%, 6 to <10%, 10 to <20%, and ≥20%; for 5 
years, 0 to <5%, 5 to <15%, 15 to <25%, 25 to <50%, ≥50%. In the absence of clinical 
practice guidelines that recommend risk cut-offs/strata for CKD progression, the risk 
categories used were adopted from the original development study and subsequent CKD-PC 
publications.6 Calibration varied across cohorts; thus, factors that might explain 
heterogeneity in baseline risk were investigated by regressing cohort-specific baseline risk 
on cohort characteristics (e.g., region of cohort, mean eGFR, proportion of the cohort with 
African American ethnicity, diabetes mellitus, and hypertension). Baseline risk was 
estimated for each cohort using Cox proportional hazards models, holding the variable 
coefficients constant and equal to the original KFRE regression coefficients, but allowing 
the intercept to vary. The only cohort characteristic associated with cohort-specific baseline 
hazard was region of cohort, with higher baseline risk in North American cohorts compared 
with non-North American cohorts.
Regional variation in baseline risk was then addressed through the development of two 
regional calibration factors (North America and non-North America). The regional 
calibration factors were developed as the ratio of the event-weighted regional mean to the 
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original baseline hazard. A Brier Score, the squared difference between the observed vs. 
predicted binary outcomes (observed minus predicted risk), was used to evaluate whether 
calibration improved with the “regional-calibrated original” KFREs, in each study.20 The 
Wilcoxon sign-rank test was used to evaluate the differences in Brier Score between original 
and regional-calibrated original KFREs. An overall Brier Score was calculated using event-
weighted means. The square-root of this overall score was reported as the root-mean-
squared error between observed and predicted risk. A p-value <0.05 was considered 
statistically significant. All tests were 2-sided. All analyses were performed using Stata MP 
13 (College Station, TX).
Results
There were 721,357 CKD patients and 23,829 kidney failure events in 31 cohorts with an 
average follow-up time of 4.2 years (Table 1). A total of 16 cohorts (617,604 patients) were 
based in North America, and 15 cohorts (103,753 patients) were from Asia, Europe and 
Australasia. Missing data varied by cohort (median of 0%, 1%, and 41% for the 4-, 6-, and 
8-variable equations; eAppendix 1). The amount of missing data was higher in North 
American cohorts (median missing for 4-variable, 6-variable, and 8-variable KFREs: 2%, 
3%, 79%) than in non-North American cohorts (median missing: 0%, 1%, and 9%). All 31 
cohorts had the variables necessary to validate the 4-variable KFREs, 29 cohorts had the 
variables necessary to validate the 6-variable KFREs, and 16 cohorts had the variables 
necessary to validate the 8-variable KFREs.
The mean age of the study population was 74 years, and the mean baseline eGFR was 46 
ml/min/1.73 m2. Cohorts ranged from being predominantly male (Veterans Administration 
CKD, 97%) to majority female (Okinawa-83, 75%). Forty percent of the patients had 
diabetes, and 84% had hypertension (eTable 1). Forty percent of the study participants had a 
baseline urinary ACR ≥30 mg/g. The observed incidence of kidney failure ranged from 1.2 
events per 1,000 person-years in Okinawa to 168.3 events per 1,000 person-years in the 
Pima Indian cohort. According to the original 4-variable KFRE, the proportion of each 
cohort who had a >20% 2-year predicted probability of kidney failure ranged from 0.23% 
(Okinawa93 cohort) to 50% (CRIB cohort).
Variable Coefficients in the Original and Pooled KFRE
In general, coefficients for the association between different characteristics (e.g. age, sex, 
eGFR, ACR) and the risk of kidney failure were similar in the original and pooled KFREs 
(Table 2). Exceptions were eGFR in the 4-variable equations (original vs. pooled: HR 0.57 
vs. 0.63 per 5 ml/min/1.73 m2 higher eGFR) and serum bicarbonate in the 8-variable 
equations (0.93 vs. 0.99 per 1 mEq/L higher serum bicarbonate), both of which were 
stronger in the original KFRE.
Discrimination
Measures of discrimination for the original 4-variable KFRE were excellent for the 2-year 
and 5-year predicted probability of kidney failure (Figure 1). Overall, the 4-variable 
equation had a pooled C statistic of 0.90 (95% CI 0.89–0.92) at 2 years, and 0.88 (95% CI 
Tangri et al. Page 6
JAMA. Author manuscript; available in PMC 2017 January 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
0.86–0.90) at 5 years. Within individual cohorts, discrimination was also excellent, with C 
statistic >0.80 in all but two cohorts (MMKD 2-year C statistic 0.79 (95% CI 0.72–0.87), 
MASTERPLAN 5-year C statistic 0.77 (95% CI 0.73–0.81). Discrimination for the original 
8-variable KFRE was 0.89 (95% CI 0.88–0.91) at 2 years and 0.86 (95% CI 0.84–0.87) at 5 
years (eFigure 1). In pre-specified subgroups of age, sex, race, region and diabetes status, 
discrimination was qualitatively unchanged, with C statistics for the 4-variable KFRE 
ranging from 0.90 to 0.92 for 2 years and 0.87 to 0.89 for 5 years (Figure 2). Similar 
statistics for the 6-variable equation are shown in eFigure 2.
In general, the pooled 4-and 8-variable KFREs resulted in similar discrimination to the 
original KFREs (eTables 2–7). There was no significant difference in the overall C statistics 
of the pooled and the original KFREs (4-variable KFRE over 2 years: −0.0006, 95% CI 
−0.0020 −0.0008). When 2-year risk in all 31 cohorts was assessed individually, the pooled 
4-variable KFRE performed significantly better than the original 4-variable KFRE in 5 
cohorts, and in 5 cohorts it performed significantly worse (p<0.05 for each comparison).
Discrimination of the 8-variable KFRE was slightly better than the 4-variable KFRE in 
cohorts that had the necessary components for both equations (eTables 8 and 9). This was 
true using either the original KFRE or the pooled KFRE and in nearly all subgroups of 
interest.
Calibration
Plots of the observed versus predicted risk demonstrated differences in calibration, with 
suboptimal performance in some of the non-North American cohorts (eFigures 3–6 for 
North American cohorts; eFigures 7–10 for non-North American cohorts). Baseline risk 
varied by region, with higher levels in North America compared with non-North America 
using the 4-variable equation (Figure 3). There was slightly less variation in baseline risk by 
region using the 8-variable equation (eFigure 11). In non-North American studies, use of a 
regional calibration factor that lowered the baseline risk by 32.9% at 2 years and 16.5% at 5 
years decreased the root mean-squared distance of the observed to expected risk from 0.237 
to 0.228 at 2 years and 0.299 to 0.287 at 5 years for the 4-variable equation and improved 
performance in 12 out of 15 studies at 2 years (p=0.04) and 10 out of 13 studies at 5 years 
(p=0.02) (eTable 10). In contrast, use of a regional calibration factor in North American 
cohorts, the region where the KFREs were developed, did not significantly improve 
performance. For example, the root mean-squared distance of the observed to expected risk 
at 2 years only minimally changed from 0.152 to 0.151 with the addition of the calibration 
factor and increased from 0.264 to 0.272 at 5 years for the 4-variable equation. eAppendix 2 
shows all equations.
Discussion
In this collaborative meta-analysis of 721,357 patients, across 31 cohorts and over 30 
countries, the KFREs accurately predict the 2-year and 5-year probability of kidney failure 
in patients with CKD with a wide range of variation in age, sex, race, and in the presence or 
absence of diabetes.
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The original equations reported by Tangri et al demonstrated excellent discrimination and 
appropriate calibration in the majority of the North American cohorts, and addition of a 
recalibration factor optimized performance in non-North American populations. The 4-
variable KFRE (age, sex, eGFR, and albuminuria) can be easily implemented in electronic 
medical records and laboratory information systems. The use of this equation is consistent 
with the KDIGO guideline which recommends integration of risk prediction in the 
evaluation and management of CKD,21 and is in agreement with a strong body of evidence 
demonstrating the importance of eGFR and albuminuria in predicting prognosis.13,15,22–35
Previous investigators developed alternative risk prediction models for progression of CKD 
to kidney failure,36 but most have not been externally validated. The KFREs developed by 
Tangri et al were externally validated in a cohort of Canadian CKD patients referred for 
nephrology care, but their accuracy in non-referred patients and regions outside Canada 
remained unknown. Thus, current clinical practice guidelines recommended the use of 
KFREs for predicting prognosis and planning dialysis access, but with appropriate caution 
regarding their external validity.37 The current validation study addresses these concerns, 
and more widespread clinical assessment of the KFREs can now be recommended. Similar 
to previous work, an incremental improvement in performance was observed with an 8-
variable KFRE, which additionally includes serum albumin, phosphate, bicarbonate, and 
calcium levels over the 4-variable KFRE. The magnitude of improvement was smaller than 
in the original study, but may be meaningful for patients where data for both equations is 
readily available. These findings suggest that the 4-variable KFRE might be adopted more 
widely, but the 8-variable KFRE should be made available if the additional variables are 
obtained and increased precision is desired.
The risk associations observed in the pooled validation sample were similar to those in the 
original KFRE. In particular, younger age, male sex, lower eGFR and higher albuminuria 
were associated with a higher risk of kidney failure defined by treatment with dialysis or 
transplant. The finding of lower risk of kidney failure with older age is consistent with the 
previous literature25 and is likely due to a combination of factors: 1) the same disease 
process (e.g., diabetic nephropathy in a patient with type 1 diabetes with age of diagnosis at 
15 years) is more likely to be indolent, if the patient has an eGFR of 30 ml/min/1.73 m2 at 
age 75 (60 years of exposure) vs. age 45 (30 years of exposure); 2) as patients age, they are 
more likely to die from a competing cause (malignancy, cardiovascular disease) than reach 
kidney failure; and 3) older patients may be more likely to choose conservative care for 
kidney failure rather than treatment with dialysis or transplant, our primary outcome.38 It is 
important to note that in the original development of the KFRE,6 competing risk models 
were evaluated and a threshold of eGFR of <10 ml/min/1.73 m2 was tested as a secondary 
outcome; no differences in the performance of the KFREs was observed.
Although recalibration was not needed in most North American cohorts, adding a regional 
calibration factor in non-North American cohorts improved calibration and would allow the 
KFREs to be used clinically in countries with different levels of baseline risk. This is similar 
to the Framingham Study Equation, which is used for estimating cardiovascular risk and has 
been recalibrated for use in multiple different populations.19 Differences in baseline risk 
between cohorts and regions may reflect different cohort inclusion criteria, or treatment 
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preferences for kidney failure rather than physiological differences in disease progression, 
since risk relationships between the risk factors and kidney failure were fairly uniform 
across settings. Further studies examining additional causes of heterogeneity in higher vs. 
lower risk populations are needed.
There are important clinical and research implications to this study’s findings. Clinicians can 
now use the 4- or 8-variable KFRE, with the recalibration factor where applicable, and 
inform patient-clinician communication and treatment decisions around the absolute risk of 
kidney failure, rather than the CKD Stage alone. Decisions regarding access placement or 
transplant referral could be made once kidney failure risk thresholds are exceeded. Some 
kidney failure risk thresholds have been proposed on the basis of physician surveys and 
decision analyses (>3 or 5% risk for 5 years for nephrology referral, >20 or 40% risk over 2 
years for vascular access planning), and should be evaluated further in cluster randomized 
trials or time series analyses. Routine reporting and clinical implementation is already 
underway in several centers, and its impact on patient care and health services is being 
studied. From a research perspective, the KFRE can be used to estimate event rates and 
statistical power for kidney failure outcomes in clinical trials, and may be useful in selecting 
higher-risk patients for trial inclusion and identifying risk-treatment interactions.39,40
This study has limitations. First, the KFRE does not assess kidney failure risk in patients 
with CKD Stages G1 (GFR ≥90 ml/min/1.73m2) and G2 (GFR 60–89 ml/min/1.73m2). 
Previous studies have shown that patients with Stages G1–2 and high levels of albuminuria 
should be considered as high risk. Second, due to the variables required, validation of the 8-
variable equation was not possible in all cohorts. Therefore, nested comparisons between 
equations are limited to a subset. In some cohorts, proteinuria was converted to albuminuria, 
and although no meaningful differences in discrimination were observed in these 
populations, it is possible that risk relationships may differ slightly for the two measures. 
Furthermore, even with the inclusion of more than 700,000 participants in over 30 countries, 
there was not significant representation from countries where there is limited access to renal 
replacement therapy. Validation in these countries with a combined endpoint of treated and 
untreated kidney failure should be performed. Third, there were missing data, particularly in 
the North American health systems. Missing data reduces the generalizability of our findings 
to North American health systems. While this generalizability applies to the hypothetical 
world of all patients, the results do reflect participants as they would be used in clinical 
health systems. Furthermore, KFRE performance was similar in health system and research 
cohorts. Fourth, the risk equations provide the risk of kidney failure over 2 and 5 years. 
These timeframes are important for decisions regarding nephrology referral, dialysis access 
planning and pre-emptive transplantation (i.e., kidney transplant prior to receiving dialysis), 
but they do not capture longer-term risk of kidney failure, which may impact other clinical 
decisions such as lifestyle modification.41 Fifth, the KFRE incorporates routinely collected 
laboratory data. Accuracy of risk predictions may be enhanced in specific subpopulations by 
novel biomarkers of CKD; however, the incremental gain in predictive accuracy may not be 
justified by the cost of these newer assays for the entire CKD population.42 Sixth, there is no 
evidence that using the equation will improve outcomes. Well-designed pragmatic 
randomized trials are needed to definitively establish the evidence for efficacy.
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Strengths of this study include the large patient population, and accompanying diversity in 
age, sex, race and etiology of kidney disease. In North America, the 4-variable original 
KFRE appears generalizable and highly accurate in most cohorts and can be easily 
implemented across multiple health care systems. Elsewhere, the recalibrated KFRE appears 
more accurate, and can also be integrated into healthcare platforms. Partnerships with 
mobile technology developers and health care systems may ensure that knowledge 
translation occurs without long delays, which are common in biomedical research.
Conclusions
KFREs developed in a Canadian population showed high discrimination and adequate 
calibration when validated in 31 multinational cohorts. However, in some regions the 
addition of a calibration factor may be necessary.
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Figure 1. Discrimination statistics (C statistics) for original 4-variable equation at 2 and 5 years 
by cohort
An asterisk indicates this cohorts measuring dipstick proteinuria. Due to a limited number of 
events, confidence intervals were wide in some studies and therefore capped at 1.00 
(maximum value for C statistic). Size is proportional to the weight of the study in a random 
effects meta-analysis. Arrows indicate that the true values are beyond the range of the axis. 
Representative references and expanded acronyms for each cohort name are provided in 
eAppendix 3.
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Figure 2. Discrimination statistics (C statistics) for original 4-variable and 8-variable equations 
at 2 and 5 years by subgroup
In the 4-variable equation analyses, 31 cohorts contributed for 2-year analysis and 26 
cohorts for 5-year analysis. In the 8-variable equation analyses, 16 cohorts contributed for 2-
year analysis and 11 cohorts contributed for 5-year analysis.
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Figure 3. Refit baseline hazard of original 4-variable equation at 2 and 5 years in individual 
cohorts stratified by region
Horizontal gray line represents the centered baseline hazard for the original 4-variable 
KFRE (age 70 years, male 56%, eGFR 36 ml/min/1.73 m2, ACR 170 mg/g); the red and 
green horizontal line represent the weighted mean refit baseline hazard within each region 
(North America and non-North America). NA: North America, NZ: New Zealand, E: 
Europe, I: Israel, A: Asia. The 25 cohorts included represent studies with available urine 
albumin-to-creatinine ratio. Studies with dipstick proteinuria were not included in the 
calculation. The North America cohorts include AASK, ARIC, BC CKD, CCF_ACR, CRIC, 
Geisinger, ICES-KDT, MDRD, Mt Sinai BioMe, Pima, REGARDS, Sunnybrook, and VA 
CKD. The New Zealand cohort is NZDCS. The Europe cohorts include CRIB, GCKD, 
GLOMMS-1, HUNT, MASTERPLAN, MMKD, Nephrotest, RENAAL, and SRR-CKD. 
The Israel cohort is Maccabi. The Asia cohort is Gonryo.
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